| Lipids Management |
1 |
1 |
| PCSK9 |
0 |
0.99 |
| Statins |
0 |
0.47 |
| Cardiovascular Risk Management |
0 |
0.44 |
| LDL Cholesterol |
0 |
0.43 |
| Infarction |
0 |
0.2 |
| Acute Myocardial Infarction (MI) |
0 |
0.17 |
| Hospital |
0 |
0.17 |
| Myocardial Infarction (MI) |
0 |
0.9 |
| Acute Coronary Syndrome |
0 |
0.1 |
| Adherence |
0 |
0.1 |
| Clinical Guidelines |
0 |
0.1 |
| Grant |
0 |
0.1 |
| ST Segment Elevation Myocardial Infarction |
0 |
0.98 |
| Cerebrovascular Accident |
0 |
0.06 |
| Percutaneous Coronary Intervention |
0 |
0.06 |
| Thromboembolism |
0 |
0.05 |
| Angiography |
0 |
0.03 |
| Artery |
0 |
0.03 |
| Biologic Therapy |
0 |
0.03 |
| Biomarker |
0 |
0.03 |
| Blood |
0 |
0.03 |
| Board Certification |
0 |
0.03 |
| Cardiovascular Imaging |
0 |
0.03 |
| COVID-19 |
0 |
0.03 |
| Europe |
0 |
0.03 |
| Geriatrics |
0 |
0.03 |
| Ischemic Stroke |
0 |
0.03 |
| Monoclonal Antibody |
0 |
0.03 |
| New York |
0 |
0.03 |
| Pandemic |
0 |
0.03 |